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Gamma interferon blocks gammaherpesvirus reactivation from
latency in a cell type-specific manner
Abstract
Gammaherpesviruses are important pathogens whose lifelong survival in the host depends critically on
their capacity to establish and reactivate from latency, processes regulated by both viral genes and the
host immune response. Previous work has demonstrated that gamma interferon (IFN-gamma) is a key
regulator of chronic infection with murine gammaherpesvirus 68 (gammaHV68), a virus that establishes
latent infection in B lymphocytes, macrophages, and dendritic cells. In mice deficient in IFN-gamma or
the IFN-gamma receptor, gammaHV68 gene expression is altered during chronic infection, and
peritoneal cells explanted from these mice reactivate more efficiently ex vivo than cells derived from
wild-type mice. Furthermore, treatment with IFN-gamma inhibits reactivation of gammaHV68 from
latently infected wild-type peritoneal cells, and depletion of IFN-gamma from wild-type mice increases
the efficiency of reactivation of explanted peritoneal cells. These profound effects of IFN-gamma on
chronic gammaHV68 latency and reactivation raise the question of which cells respond to IFN-gamma
to control chronic gammaHV68 infection. Here, we show that IFN-gamma inhibited reactivation of
peritoneal cells and spleen cells harvested from mice lacking B lymphocytes, but not wild-type spleen
cells, suggesting that IFN-gamma may inhibit reactivation in a cell type-specific manner. To directly test
this hypothesis, we expressed the diphtheria toxin receptor specifically on either B lymphocytes or
macrophages and used diphtheria toxin treatment to deplete these specific cells in vivo and in vitro after
establishing latency. We demonstrate that macrophages, but not B cells, are responsive to
IFN-gamma-mediated suppression of gammaHV68 reactivation. These data indicate that the regulation
of gammaherpesvirus latency by IFN-gamma is cell type specific and raise the possibility that cell
type-specific immune deficiency may alter latency in distinct and important ways.
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Gammaherpesviruses are important pathogens whose lifelong survival in the host depends critically on their
capacity to establish and reactivate from latency, processes regulated by both viral genes and the host immune
response. Previous work has demonstrated that gamma interferon (IFN-) is a key regulator of chronic
infection with murine gammaherpesvirus 68 (HV68), a virus that establishes latent infection in B lympho-
cytes, macrophages, and dendritic cells. In mice deficient in IFN- or the IFN- receptor, HV68 gene
expression is altered during chronic infection, and peritoneal cells explanted from these mice reactivate more
efficiently ex vivo than cells derived from wild-type mice. Furthermore, treatment with IFN- inhibits reacti-
vation of HV68 from latently infected wild-type peritoneal cells, and depletion of IFN- from wild-type mice
increases the efficiency of reactivation of explanted peritoneal cells. These profound effects of IFN- on chronic
HV68 latency and reactivation raise the question of which cells respond to IFN- to control chronic HV68
infection. Here, we show that IFN- inhibited reactivation of peritoneal cells and spleen cells harvested from
mice lacking B lymphocytes, but not wild-type spleen cells, suggesting that IFN- may inhibit reactivation in
a cell type-specific manner. To directly test this hypothesis, we expressed the diphtheria toxin receptor
specifically on either B lymphocytes or macrophages and used diphtheria toxin treatment to deplete these
specific cells in vivo and in vitro after establishing latency. We demonstrate that macrophages, but not B cells,
are responsive to IFN--mediated suppression of HV68 reactivation. These data indicate that the regulation
of gammaherpesvirus latency by IFN- is cell type specific and raise the possibility that cell type-specific
immune deficiency may alter latency in distinct and important ways.
The human gammaherpesviruses are important pathogens,
particularly given their association with lymphomas and lym-
phoproliferative disease in immunocompromised patients.
Given the strict species specificity of Epstein-Barr virus (EBV)
and Kaposi’s sarcoma-associated herpesvirus (KSHV) and the
complexity of clinical studies in infected humans, we have
turned to analysis of infection of mice with gammaherpesvirus
68 (HV68) as a tractable small-animal pathogenesis and im-
munologic model for understanding the dynamics and genetics
of chronic and latent gammaherpesvirus infection. HV68 was
isolated from a bank vole and infects both outbred and labo-
ratory mice. Moreover, HV68 infection is associated with the
development of lymphomas and lymphoproliferative disease in
mice (27, 30).
Similar to human gammaherpesviruses, HV68 establishes
both an acute lytic infection and a lifelong latent infection.
Human gammaherpesviruses have a propensity to establish
latent infection in lymphoid organs, such as spleen and lymph
nodes (EBV and KSHV), or in pleural and peritoneal cells
(KSHV). Acute HV68 infection is detectable in multiple or-
gans, while chronic infection is found in the spleen, bone mar-
row, lung, and peritoneal cells (11, 26, 28, 29, 33, 35, 36), where
the virus persists in B cells, macrophages, and dendritic cells
(10–12, 29, 35, 36). Control of chronic gammaherpesvirus in-
fection is of particular interest given that reactivation from
latency and persistent replication likely contribute to viral
spread and disease pathogenesis. Previous work identified
gamma interferon (IFN-) as a key regulator of HV68 reac-
tivation from latency (25, 31, 34). Mice genetically deficient in
IFN- or IFN- receptor (IFN-R) are unable to control
chronic HV68 infection, as evidenced by increased efficiency
of reactivation from latency and persistent low-level productive
infection (25, 31). IFN-/ and IFN-R/ mice ultimately
develop a large-vessel vasculitis which is dependent on viral
replication in the immunoprivileged media of the great elastic
arteries (8, 34). Moreover, the addition of IFN- to wild-type
latently infected peritoneal cells ex vivo significantly reduces
the frequency of reactivation events (25).
While it is clear that IFN- signaling is essential for the
control of chronic gammaherpesvirus infection, the mechanism
by which IFN- exerts its effects and the relevant cell types
targeted by IFN- are unknown. Based on our previous stud-
ies, it is likely that IFN- suppresses reactivation from latency
by signaling directly to infected cells (25). Given that B cells
and macrophages constitute the predominant cell types that
harbor latent virus in splenocytes and peritoneal cells, we in-
vestigated whether one or both of these cell types represent the
relevant targets of IFN- for suppression of HV68 reactiva-
tion.
IFN- inhibits reactivation of HV68 in peritoneal cells, but
not splenocytes. As previously reported (25), IFN- treatment
suppresses the frequency of HV68 reactivation from perito-
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neal cells harvested from latently infected mice in an ex vivo
reactivation assay (Fig. 1A). Peritoneal cells harvested from
animals 16 days postinfection plated in medium alone reacti-
vated with an approximate frequency of 1/1,000, while cells
treated with 100 units/ml of IFN- reactivated at a substantially
lower frequency, conservatively 1/40,000. In contrast, spleno-
cytes harvested from mice 16 days postinfection reactivate
HV68 at a frequency of approximately 1/10,000 when plated
in either medium only or treated with 100 units/ml of IFN-
(Fig. 1B). Viral reactivation from latency was solely responsi-
ble for the observed cytopathic events, as mechanical disrup-
tion of parallel samples resulted in no cytopathic effect (CPE)
(data not shown).
Previous work from our laboratory supports the notion that
IFN- has site-specific effects on HV68 reactivation. Specif-
ically, in IFN-/ deficient mice, reactivation from latency is
dramatically increased in peritoneal cells, while viral reactiva-
tion from splenocytes is slightly decreased compared to wild-
type cells (31).
Together these data demonstrate that IFN- exerts its ef-
fects selectively, altering reactivation from peritoneal cells but
not splenocytes. Given that the predominant latent reservoir of
HV68 in peritoneal cells is the macrophage, and in the spleen
it is the B cell (36, 37), we hypothesized that the difference in
the ability of IFN- to suppress reactivation in cells derived
from these two anatomic sites reflects a cell type-specific effect
of IFN- on HV68 reactivation.
IFN- inhibits reactivation of HV68 in peritoneal cells and
splenocytes from B-cell-deficient mice. One prediction of this
model was that B cells, the predominant cell carrying latent
HV68 in the spleen, would be unresponsive to the effects of
IFN-. To investigate whether IFN- can suppress HV68
reactivation from latency in splenocytes lacking B cells, we
examined the effect of IFN- on HV68 reactivation in spleno-
cytes from B-cell-deficient (MT) animals. These mice are
deficient in mature B cells due to a homozygous mutation in
the  heavy-chain transmembrane exon (17). Previous work
has demonstrated that HV68 latency is established in both
peritoneal cells and splenocytes in the absence of mature B
cells in these mice (19, 33). Despite the fact that B cells are the
predominant cell type harboring HV68 latency in the spleen
in wild-type mice (37), splenocytes from B-cell-deficient mice
reactivate latent HV68 virus (19, 33).
Consistent with prior investigations, HV68 reactivated
from MT peritoneal cells 16 days postinfection with a fre-
quency of 1/127 (Fig. 2A). IFN- treatment decreased the
frequency of cells reactivating HV68 to 1/3,232, an approxi-
mate 25-fold decrease. Strikingly, the addition of IFN- to
splenocytes lacking B cells also significantly reduced the fre-
quency of cells reactivating HV68 (Fig. 2B). Approximately
1/17,000 splenocytes from B-cell-deficient mice reactivated
from latency when plated in medium only, and addition of 100
units/ml of IFN- reduced the frequency of reactivation events
to negligible levels. These results demonstrate that IFN- can
suppress reactivation of HV68 in both the peritoneal cell and
splenocyte populations harvested from B-cell-deficient ani-
mals. This suggests that IFN- acts on non-B cells to inhibit
reactivation.
Strategy for selective depletion of B cells and macrophages
in vivo. In order to further investigate the cell type-specific
effects of IFN- on HV68 reactivation, we employed a genetic
strategy to deplete specific cells in a temporally controlled
fashion. To accomplish this, we bred mice carrying both a Cre
recombinase-inducible simian diphtheria toxin receptor (DTR) in
the ROSA26 locus (iDTR mice [4]) and Cre recombinase ex-
pressed specifically in either B cells (CD19-Cre) or macro-
phages (lysozyme-Cre). Injection of diphtheria toxin into
iDTR/Cre mice allows the specific depletion of DTR-express-
ing macrophages or B cells in a temporally controlled manner.
This system has several advantages. Most importantly, it allows
the depletion of macrophages or B cells after the establishment
of latency. This enables us to analyze immune control of la-
tency in mice with normal immune systems.
Selective depletion of B cells after the establishment of
HV68 latency in vivo. To generate mice in which B cells can
be acutely depleted, we bred iDTR mice with mice expressing
Cre from the B-cell-specific CD19 promoter (CD19-Cre) (22)
to generate iDTR/CD19-Cre mice. CD19 is expressed through-
out B-cell development (18, 38).
iDTR/CD19-Cre mice were infected with HV68. Sixteen
FIG. 1. IFN- inhibits reactivation of HV68 in peritoneal cells,
but not splenocytes, isolated from latently infected wild-type mice.
(A) Ex vivo reactivation assay demonstrating that HV68 latently
infected peritoneal cells treated with 100 U/ml of IFN- reactivate at
a lower frequency than peritoneal cells treated with medium only.
(B) In contrast to peritoneal cells, IFN- treatment of splenocytes did
not alter the frequency of HV68 reactivation. Reactivation from
latency was assayed by plating limiting dilutions of cells onto permis-
sive MEF monolayers and scoring for CPE as a result of infectious
virus 3 weeks later. Serial twofold dilutions of cells (24 wells/dilution)
were plated onto an indicator monolayer of IFN-R/ MEFs in
96-well tissue culture plates. To distinguish between reactivation from
latency and preformed infectious virus present in these cells, we plated
parallel cell samples after mechanical disruption.
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days later, mice were injected with either 100 ng of diphtheria
toxin (DT) or bovine serum albumin (BSA) (control) once a
day for 7 days. Peritoneal cells were then harvested and ana-
lyzed by flow cytometry for macrophages (F480), B cells
(CD19), T cells (CD4 and CD8), and dendritic cells (Cd11c,
analyzed in the spleen only) to ascertain the extent and spec-
ificity of depletion. DT administration did not affect dendritic
cells or CD4 or CD8 T cells (data not shown). In contrast,
significant depletion of B cells from the peritoneal cell popu-
lation (94% depletion) was demonstrated in the iDTR/CD19-
Cre mice treated with DT compared to mock-treated animals
(Fig. 3A).
Depletion of B cells from peritoneal cells does not affect the
frequency of cells reactivating HV68. We first determined
whether B cells are required for reactivation or IFN--medi-
ated suppression of HV68 latency from peritoneal cells. Cells
harvested from iDTR/CD19-Cre mice treated with DT or BSA
after the establishment of latency were analyzed in explant
reactivation assays. Peritoneal cells from mock-treated animals
reactivated at a frequency of approximately 1/14,500 (Fig. 4A).
Cells harvested from iDTR/CD19-Cre mice treated with DT
demonstrated no differences in the frequency of reactivation
compared to cells from mock-treated animals despite signifi-
cant depletion of B cells. These results indicate that, consistent
with prior studies using flow cytometry to sort cell populations
(36), B cells are not the primary peritoneal cells responsible for
HV68 reactivation. IFN- significantly reduced the frequency
of reactivation in peritoneal cells harvested from either DT- or
mock-treated iDTR/CD19-Cre animals, indicating that perito-
neal cell types other than B cells, likely macrophages, are the
target for IFN--mediated suppression of reactivation.
Selective depletion of macrophages expressing high levels of
F480 (F480high macrophages) in the peritoneal cell population
after the establishment of HV68 latency in vivo. To investi-
gate the importance of macrophages in IFN--mediated sup-
pression of HV68 reactivation after the establishment of la-
tency, we bred iDTR mice to mice expressing Cre from the
endogenous lysozyme M locus (Lyz-Cre) (6). Lysozyme M
expression is restricted to myelomonocytic cells, specifically
macrophages and neutrophil granulocytes (3, 7, 9). iDTR/Lyz-
Cre mice were infected with HV68, and after the establish-
ment of latency 16 days postinfection, the mice were injected
with DT or BSA once a day for 7 days. Peritoneal cells were
then harvested and subjected to fluorescence-activated cell
FIG. 2. IFN- inhibits reactivation of HV68 in peritoneal cells
and splenocytes isolated from latently infected B-cell-deficient mice.
(A) Ex vivo reactivation assay demonstrating that compared to treat-
ment with medium only, IFN- (100 U/ml) treatment of latently in-
fected peritoneal cells isolated from B-cell-deficient mice (MT) re-
duces the frequency of HV68 reactivation. (B) In contrast to
splenocytes isolated from wild-type mice, IFN- treatment of latently
infected B-cell-deficient splenocytes reduces the frequency of HV68
reactivation compared to treatment with medium only.
FIG. 3. Depletion of B cells and macrophages from the peritoneal
cavities of iDTR/CD19-Cre and iDTR/Lyz-Cre mice treated with diph-
theria toxin. Representative fluorescence-activated cell sorting analysis
of peritoneal cells isolated from DT-treated (green) and mock-treated
(red) iDTR/CD19-Cre (A) and iDTR/Lyz-Cre (B) latently infected
animals. (A) Intraperitoneal injection of 100 ng of DT daily for 7 days
led to significant depletion of CD19-positive cells from iDTR/CD19-
Cre mice. (B) Intraperitoneal injection of 100 ng DT daily for 7 days
resulted in a significant reduction of F480high cells from iDTR/Lyz-Cre
mice. F480 staining for macrophages is shown on the y axis, and CD19
staining for B cells is shown on the x axis.
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sorting analysis. No differences in the dendritic, CD4, or CD8
T-cell populations in harvested peritoneal cells were observed
between DT- and mock-treated animals (data not shown). DT
treatment resulted in about a 50% depletion of macrophages
expressing F480 (Fig. 3B). The F480 monoclonal antibody rec-
ognizes a macrophage-restricted 160-kDa glycoprotein (1, 13–
16, 20). Of the F480-positive peritoneal cells harvested from
the DT-treated mice, the mean fluorescence intensity of F480
staining was markedly decreased compared to that of perito-
neal cells harvested from the mock-treated animals. Thus, DT
selectively deleted F480high macrophages, leaving a macro-
phage population expressing low levels of F480. Additionally,
analysis of forward and side scatter revealed that DT treatment
resulted in loss of a significant proportion of large and granular
peritoneal cells (data not shown).
Depletion of F480high macrophages from peritoneal cells
significantly reduces the frequency of cells reactivating
HV68. To determine whether macrophages play a cell type-
specific role in IFN--mediated suppression of HV68 latency,
we next analyzed peritoneal cells harvested from iDTR/Lyz-
Cre mice treated with once-daily DT or BSA injections for 7
days after the establishment of latency in the ex vivo reactiva-
tion assay. Peritoneal cells harvested from the mock-treated
animals reactivated at a frequency of 1/5,250 (Fig. 4B). Cells
harvested from the DT-treated iDTR/Lyz-Cre mice reacti-
vated at a low frequency, conservatively 1/20,000, a statistically
significant decrease in the frequency of reactivation compared
to cells from the mock-treated animals (P  0.01). These data
demonstrate that cells expressing Cre from the lysozyme M
promoter are responsible for the majority of the reactivation
events from the peritoneal cell population.
As expected, IFN- treatment of cells from mock-treated
animals significantly reduced the frequency of reactivation,
conservatively 1/20,000 (Fig. 4B). IFN- treatment of perito-
neal cells harvested from DT-treated iDTR/Lyz-Cre animals
also reduced the frequency of cells reactivating HV68, con-
servatively 1/20,000. These data were consistent with the in-
terpretation that IFN- inhibits reactivation of HV68 from
macrophages, but interpretation of this experiment was com-
plicated by the presence of a residual F480-positive population
in DT-treated iDTR/Lyz-Cre mice.
Macrophages but not B cells are responsible for reactiva-
tion of latent HV68 from peritoneal cells. To further address
the hypothesis that macrophages are the target of IFN--me-
diated suppression of HV68 reactivation, we used treatment
of explanted cells with DT. We harvested latently infected cells
and treated them with either BSA or 100 ng/ml of DT in vitro
upon explant in the limiting dilution reactivation assay.
First, to confirm the validity of explant reactivation assays in
the presence of DT, we examined whether addition of DT
affected our capacity to detect HV68 CPE on the indicator
monolayers of murine embryonic fibroblasts used to detect
HV68 reactivation. HV68 was diluted onto indicator layers
of mouse embryonic fibroblasts (MEFs) in the presence or
absence of DT (100 ng/ml), IFN- (100 units/ml), or both DT
and IFN- together (Fig. 5). None of these treatments altered
detection of HV68 infection. As we utilize IFN-R/
MEFs in this assay, we did not expect IFN- to have any effect
of reactivation, confirming the results of earlier studies (25).
iDTR/Lyz-Cre and iDTR/CD19-Cre animals were infected
with HV68, and peritoneal cells were harvested 16 days later
after the establishment of latency. These cells were placed into
FIG. 4. Macrophages but not B cells are responsible for HV68
reactivation from latently infected peritoneal cells. (A) Compared to
controls, depletion of B cells from the peritoneal cavities of latently
infected mice (iDTR/CD19-Cre) does not affect the frequency of peri-
toneal cells reactivating HV68. Moreover, depletion of B cells did not
alter the ability of IFN- to suppress viral reactivation. (B) Depletion
of macrophages from the peritoneal cavities of latently infected mice
(iDTR/Lyz-Cre) significantly reduced the frequency of peritoneal cells
reactivating HV68. IFN- treatment reduced the frequency of reac-
tivation from both mock-treated and macrophage-depleted peritoneal
cells.
FIG. 5. DT and IFN- treatment of MEFs do not affect the ability
of HV68 to induce CPE. HV68 was added in a limiting dilution
fashion to indicator MEF monolayers treated with DT and/or IFN-.
The ability of HV68 to promote CPE in the presence of DT and/or
IFN- was unaffected after 10 days.
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explant cultures in limiting dilutions in either medium alone or
medium supplemented with DT (100 ng/ml), IFN- (100 units/
ml), or both DT and IFN- together. Cells plated in medium
alone reactivated with a frequency of approximately 1/1,000, as
expected. The addition of DT to latently infected peritoneal
cells harvested from iDTR/Lyz-Cre animals almost completely
abolished reactivation (Fig. 6A). The frequency of cells reac-
tivating HV68 in the presence of IFN--containing medium
was significantly decreased (but not eliminated). Importantly,
no reactivation was observed in any cultures treated with both
DT- and IFN--containing medium. This result likely reflects
the ability of IFN- to suppress reactivation in the small pop-
ulation of cells capable of reactivating HV68 following DT
treatment. These data demonstrate that ex vivo depletion of
Lyz-Cre-expressing cells reduces the frequency of HV68 re-
activation, allowing us to conclude that macrophages are the
predominant cell type capable of reactivating virus.
Similarly, ex vivo reactivation assays utilizing peritoneal cells
from iDTR/CD19-Cre mice treated with DT and/or IFN-
produced findings consistent with the results of our in vivo
experiments. Addition of DT to peritoneal cells from iDTR/
CD19-Cre mice in vitro did not alter the frequency of cells
reactivating HV68 (approximately 1/2,150 and 1/2,880 in the
cultures treated with medium alone and supplemented with
DT, respectively; P  0.05; Fig. 6B). Thus, B cells are not the
predominant cell type responsible for HV68 reactivation
from latently infected peritoneal cells. As expected, the ad-
dition of IFN- alone or in the presence of DT in these
cultures reduced the frequency of reactivation events signif-
icantly. These data combined with data from the above
experiments utilizing iDTR/Lyz-Cre mice indicate that mac-
rophages but not B cells are the targets for IFN- regulation
of reactivation.
Implications for cell type-specific HV68 latency. HV68
latency is established and maintained in various cellular sub-
sets in distinct anatomical locations (11, 26, 28, 29, 33, 35, 36).
For example, in peripheral blood, the major viral reservoir is
isotype-switched B cells, while chronic infection in the lung is
established in a variety of cells, including epithelial cells as well
as macrophages, B cells, and dendritic cells (10–12, 29, 35, 36).
Given these differences in cell reservoirs between different
anatomical locations, it seems likely that HV68 establishes
and maintains latency through distinct viral programs in dif-
ferent cell types. This idea is supported by the characterization
of different latency programs for EBV each with distinct pat-
terns of viral transcription (reviewed in reference 23).
The program of viral gene expression in distinct reservoirs of
HV68 latency is not well characterized. Prior studies have
uncovered that viral latency is established in distinct cell types
in various anatomical locations. For instance, in the lung, la-
tent HV68 infection can be detected in B cells, whereas in the
spleen, latent HV68 infection is established in macrophages,
dendritic cells, and B cells (11, 26, 28, 29, 33). Despite these
and other studies describing the locations and cell types har-
boring latent infection, little is known regarding potential dif-
ferences in the molecular mechanisms controlling establish-
ment and reactivation from viral latency in these distinct cell
types. Studies comparing viral gene expression from latently
infected mesenteric lymph nodes and splenocytes demonstrate
distinct expression profiles in these cell types, including M11
and K3 (24). Moreover, previous work from our laboratory has
suggested that different viral programs may operate in perito-
neal cells versus splenocytes. Comparisons of viral gene ex-
pression from latently infected peritoneal exudate cells and
splenocytes reveal significant differences in the expression lev-
els of several genes (2, 25, 31, 34). Furthermore, using nested
reverse transcription-PCR to detect transcription in genomic
areas corresponding to known latency-associated genes in
other gammaherpesviruses, different profiles of viral gene ex-
pression in latently infected peritoneal cells and splenocytes
were detected (32). Interestingly, the characterization of a
spontaneous 9.5-kb deletion mutation in HV68 revealed that
there are different genetic requirements for the establishment,
maintenance, and reactivation from latency in spleen cells
compared to peritoneal cells (5). The possibility that HV68
latency operates via distinct viral programs in different ana-
tomical locations means that the immune system may face
different challenges in controlling chronic infection in different
sites. In this paper we show that IFN- has distinct effects on
macrophages versus B cells, consistent with the concept that
immune cytokines have cell type-specific effects on viral latency
in vivo.
FIG. 6. Ex vivo DT treatment demonstrates that macrophages but
not B cells are the predominant latently infected cell responsible for
HV68 reactivation from the peritoneal cell population. (A) Ex vivo
depletion of macrophages from peritoneal cells of latently infected
mice (iDTR/Lyz-Cre) significantly reduced the frequency of peritoneal
cells reactivating HV68. IFN- treatment reduced the frequency of
reactivation of control depleted peritoneal cells. (B) Compared to
controls, ex vivo depletion of B cells from peritoneal cells isolated from
latently infected mice (iDTR/CD19-Cre) does not affect the frequency
of peritoneal cells reactivating HV68. Moreover, depletion of B cells
did not alter the ability of IFN- to suppress viral reactivation.
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Mechanisms of cell type-specific effects of IFN- on HV68
latency. One explanation for the cell type-specific effects of
IFN- lies at the level of cell type-specific responses to IFN-.
For instance, IFN- may induce an antiviral state in the mac-
rophage via cell type-specific mechanisms that are not induced
or effective in a B cell. For control of cytomegalovirus infection
in macrophages, the effects of IFN- differ dramatically in
macrophages and fibroblasts, and this correlates with distinctly
different patterns of IFN--mediated gene transcription (21).
This type of mechanism would predict that the IFN- response
of primary macrophages and B cells differs with respect to the
molecules responsible for IFN- effects on reactivation from
latency. Addressing this fundamental question will require
identification of the molecular mechanisms of IFN- inhibition
of reactivation and then comparing different cell types for
those mechanisms.
Since IFN- signaling is unable to suppress reactivation
from latency in B cells, it is likely that a separate component of
the immune system regulates viral reactivation in the B-cell
reservoir. Prior work has implicated other site-specific immune
system components, such as perforin, as necessary for the con-
trol of chronic infection (31). Perforin acts primarily in the
spleen to control the number of latently infected cells (pre-
sumably B cells). Another candidate is IFN-/, as deletion of
the IFN-/R chain 1 leads to increased reactivation and al-
tered viral gene expression in the spleen (2). In addition to
perforin and the type I interferons, it is possible that a number
of other not yet identified factors control latent infection in the
B-cell reservoir.
The existence of distinct viral latency programs and the
ability of the immune system to control chronic gammaherpes-
virus infection in a cell-specific manner have significant impli-
cations for our understanding of the mechanisms responsible
for control of gammaherpesvirus latency and likely disease
pathogenesis. Defining the different HV68 gene programs
operating in cell type-specific manners will allow the identifi-
cation of cell type-specific mechanisms of immune control of
chronic -herpesvirus infection.
H.W.V. was supported by NIH grant CA096511, A.W. was sup-
ported by the Deutsche Forschungsgemeinschaft through SFB 490,
and A.S. was supported by American Heart Association grant
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